Collegium Pharmaceutical, Inc. is a U.S.-based specialty pharmaceutical company focused on commercializing branded products for pain, attention deficit hyperactivity disorder (ADHD), and opioid-induced constipation. Its portfolio includes Xtampza ER, Belbuca, Jornay PM, the Nucynta Products, and Symproic, all sold primarily in the United States. The company’s business model depends on maintaining access to prescribers, payors, and a concentrated wholesale distribution network while managing the regulatory and reputational complexity of opioid and stimulant therapies. Collegium also relies heavily on third-party manufacturing and limited-source active pharmaceutical ingredient supply, which makes supply continuity a central part of its operating model.
23,5 %
59,3 %
8,1 %
+23,6 %
1.57
1.48
| % | |
|---|---|
| Pain portfolio | 70% Branded opioid and pain-management products including Xtampza ER, Belbuca, and the Nucynta Products. |
| ADHD portfolio | 20% Jornay PM, a branded stimulant therapy marketed for pediatric and adolescent ADHD. |
| Opioid-induced constipation | 10% Symproic, an oral treatment for opioid-induced constipation in adult patients with chronic non-cancer pain. |
Collegium sells primarily through wholesale pharmaceutical distributors, which then supply retail pharmacies, managed...
Buy product inventory in bulk and distribute it to pharmacies and other channels; they are the key commercial gatekeepers for U.S. product access.
Prescribe Xtampza ER, Belbuca, and Nucynta Products based on efficacy, dosing convenience, and abuse-deterrence profile.
Prescribe Jornay PM for pediatric and adolescent ADHD patients, valuing differentiated release profile and clinical fit.
Influence access through formulary approval, rebates, and contracting, which affect net pricing and volume.
Receive products from wholesalers and dispense them to patients in retail, hospital, clinic, nursing home, and mail-order settings.
Collegium’s business is overwhelmingly concentrated in the United States, where it commercializes all of its core...
Collegium’s strategy is centered on defending and expanding its branded pain and ADHD franchises through differentiated...
Pain products remain the core revenue engine, so maintaining prescriber share and access is essential to offset competition from branded, generic, and non-opioid alternatives.
Jornay PM adds diversification into ADHD and can reduce dependence on the pain franchise if commercial execution improves.
Net revenue depends on rebates, chargebacks, and formulary placement, making access management central to volume and pricing realization.
Limited-source APIs and outsourced manufacturing create supply risk that can interrupt commercialization if not managed tightly.
Collegium faces concentrated commercial risk because a significant share of shipments goes through only a few wholesale...
A significant percentage of shipments go to three wholesale pharmaceutical distributors, so account loss or reduced purchases would directly affect revenue and bargaining power.
The company relies on a sole supplier or limited number of suppliers for active pharmaceutical ingredients, making it vulnerable to production failures and supply disruptions.
State and federal measures can impose taxes, take-back funding, prescribing limits, and compliance burdens on opioid manufacturers.
Products compete against branded, generic, and non-opioid alternatives, which can reduce prescriptions and force pricing concessions.
Substantial indebtedness and convertible notes require ongoing cash generation and may constrain capital allocation.
CTNM · Pharmaceutical Preparations
LEXX · Pharmaceutical Preparations
Pharmaceutical Preparations
SMNR · Pharmaceutical Preparations
CORT · Pharmaceutical Preparations
Corcept Therapeutics is a U.S.-based commercial-stage pharmaceutical company focused on medicines that modulate cortisol, with its core marketed product Korlym…
LXRX · Pharmaceutical Preparations
Lexicon Pharmaceuticals is a U.S.-based biopharmaceutical company focused on discovering, developing, and commercializing small-molecule medicines.
: 11/08/2026